Schwarz Dygos Wheeler Investment Advisors LLC Reduces Stock Position in Novo Nordisk A/S (NYSE:NVO)

Schwarz Dygos Wheeler Investment Advisors LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 2.6% during the 4th quarter, Holdings Channel reports. The institutional investor owned 10,093 shares of the company’s stock after selling 270 shares during the quarter. Schwarz Dygos Wheeler Investment Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,044,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in NVO. Jennison Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock worth $2,129,761,000 after purchasing an additional 11,727,507 shares during the period. FMR LLC boosted its stake in Novo Nordisk A/S by 122.7% during the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after buying an additional 6,654,614 shares during the period. Morgan Stanley increased its position in Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock valued at $838,021,000 after acquiring an additional 4,526,199 shares during the last quarter. Loomis Sayles & Co. L P raised its stake in shares of Novo Nordisk A/S by 91.7% in the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock valued at $827,354,000 after acquiring an additional 4,350,862 shares during the period. Finally, Polen Capital Management LLC bought a new stake in shares of Novo Nordisk A/S in the 3rd quarter worth about $718,995,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on NVO shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. UBS Group initiated coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating for the company. Morgan Stanley began coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective on the stock. Finally, BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 target price for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Up 0.8 %

Shares of NVO stock traded up $1.06 during mid-day trading on Friday, hitting $126.85. The stock had a trading volume of 3,312,457 shares, compared to its average volume of 3,307,405. The firm has a market capitalization of $569.24 billion, a P/E ratio of 46.90, a price-to-earnings-growth ratio of 2.10 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28. The firm’s 50-day moving average is $126.86 and its two-hundred day moving average is $111.98.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. On average, analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Shareholders of record on Monday, March 25th were issued a dividend of $0.664 per share. The ex-dividend date of this dividend was Friday, March 22nd. This represents a yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio is currently 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.